AGM/EGMOct 19, 2026, 04:21 PM
Lantern Pharma Announces 2026 Annual Meeting of Stockholders
AI Summary
Lantern Pharma Inc. has filed its Definitive Proxy Statement for its 2026 Annual Meeting of Stockholders, scheduled for December 1, 2026, to be conducted via live audio webcast. Key proposals include the election of six directors, an increase in authorized common stock to 50 million shares, and an amendment to the Equity Incentive Plan to add 250,000 shares. Stockholders will also vote on the issuance of shares related to warrants, ratify the appointment of EisnerAmper LLP as auditor, and provide advisory votes on executive compensation and its frequency.
Key Highlights
- Lantern Pharma to hold 2026 Annual Meeting of Stockholders on December 1, 2026, via live audio webcast.
- Proposals include election of six directors, increasing authorized common stock to 50 million shares.
- Seeking approval to amend Equity Incentive Plan to add 250,000 shares.
- Vote on issuance of up to 3,669,725 shares upon exercise of warrants sold to an institutional investor.
- Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
- Advisory vote on executive compensation and preferred frequency of such votes.
Price Impact
More from LTRN